Atea Pharmaceuticals Inc. (AVIR) Social Stream
ATEA PHARMACEUTICALS INC (AVIR) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering ATEA PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 5 | $20 | $14 | $16.666 | $3.16 | 427.41% |
| 2021-11-18 | 5 | $16 | $11 | $13.666 | $3.16 | 332.47% |
| 2021-12-15 | 4 | $16 | $11 | $13.666 | $3.16 | 332.47% |
| 2022-01-04 | 4 | $14 | $10 | $11.666 | $3.16 | 269.18% |
| 2022-01-06 | 4 | $11 | $7 | $9.333 | $3.16 | 195.35% |
| 2022-01-31 | 4 | $11 | $6 | $9 | $3.16 | 184.81% |
| 2022-02-15 | 4 | $10 | $6 | $8.666 | $3.16 | 174.24% |
| 2022-02-28 | 4 | $10 | $6 | $8.333 | $3.16 | 163.7% |
| 2022-05-10 | 4 | $9 | $6 | $7.666 | $3.16 | 142.59% |
| 2022-08-09 | 4 | $12 | $6 | $9 | $3.16 | 184.81% |
| 2022-08-15 | 4 | $12 | $7 | $9.333 | $3.16 | 195.35% |
| 2022-10-12 | 4 | $12 | $7 | $9 | $3.16 | 184.81% |
| 2022-11-08 | 4 | $12 | $7 | $9 | $3.16 | 184.81% |
| 2023-01-24 | 4 | $12 | $4 | $8 | $3.16 | 153.16% |
| 2023-03-01 | 4 | $12 | $4 | $7.333 | $3.16 | 132.06% |
| 2023-08-08 | 4 | $4.001 | $4 | $4 | $3.16 | 26.58% |
| 2023-11-17 | 4 | $4 | $4 | $4 | $3.16 | 26.58% |
| 2023-12-19 | 4 | $4 | $2 | $3 | $3.16 | -5.06% |
The Trend in the Analyst Price Target
Over the past 42 weeks, AVIR's average price target has gone down $4.33.
AVIR reports an average of 51.51% for its upside potential over the past 47 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-01-27 | 4 | 12.000 | 4 | 7.333 | 4.60 | 59.41% |
| 2023-03-16 | 4 | 8.000 | 4 | 5.333 | 3.68 | 44.92% |
| 2023-08-08 | 4 | 4.001 | 4 | 4.000 | 3.41 | 17.3% |
| 2023-08-08 | 4 | 8.000 | 4 | 5.333 | 3.41 | 56.39% |
| 2023-12-19 | 4 | 4.000 | 2 | 3.000 | 3.13 | -4.15% |
AVIR Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3.17 | 1 | 0 | 1 | 1 | 1 | 4 |
The Trend in the Broker Recommendations
Over the past 39 weeks, AVIR's average broker recommendation rating worsened by 0.5.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for AVIR as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, ATEA PHARMACEUTICALS INC's average analyst price target is higher than 181.49% of them.
- In terms of how ATEA PHARMACEUTICALS INC fares relative to all US stocks, note that its number of analysts covering the stock is greater than 274.93% of that group.
- AVIR has a greater upside potential (average analyst target price relative to current price) than 1587.64% of stocks in the mid market cap category.
- In terms of how ATEA PHARMACEUTICALS INC fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -625.42% of that group.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ATEA PHARMACEUTICALS INC are LMDX, VALN, and RVMD.
View All Top Stocks by Price Target
What is the outlook for AVIR? Use POWR Ratings for clearer insight into price direction.